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OBJECTIVES: To compare signs and symptoms of dysphagia in individuals with cervical dystonia (CD) before and
after application of botulinum toxin (BTX).
METHODS: A prospective study was conducted with 20 patients diagnosed with CD with indications for BTX
application. We selected 18 patients who met the study inclusion criteria. All individuals were patients from the
Movement Disorders Unit, Department of Neurology, Federal University of Sa˜o Paulo. BTX was applied in the
cervical region at the necessary dose for each individual. To identify signs/complaints of changes in swallowing,
we used a specific questionnaire that was completed by patients and/or their companions on the day of BTX
injection and repeated 10 to 15 days after BTX injection.
RESULTS: Among the 18 study subjects, 15 (83.3%) showed primary and three (16.7%) showed secondary
cervical dystonia. The most frequent dystonic movements were rotation (18), tilt (5), forward shift (3), backward
shift (7), shoulder elevation (12), shoulder depression (2), and cervical tremor (6). The main complaints reported
before BTX application were voice changes in 10 (55.6%), need for adjustment of eating position in 10 (55.6%),
coughing and/or choking while eating in nine (50%), and increased eating time in nine (50%) individuals.
The main complaints reported after BTX application were coughing and/or choking while eating in 11 (61.1%),
voice changes in nine (50%), sensation of food stuck in the throat in eight (44%), and increased eating time in
eight (44%) individuals.
CONCLUSION: The administration of a swallowing-specific questionnaire to individuals with CD before and after
BTX application enabled the identification of possible dysphagia symptoms prior to drug treatment resulting
from CD, which are often subsequently interpreted as side effects of the drug treatment. Thus, dysphagia can be
managed, and aspiration symptoms can be prevented.
KEYWORDS: Dysphagia; Dystonia; Voice Symptoms; Botulinum Toxin; Swallowing; Aspiration.
’ INTRODUCTION
Dystonia is defined as ‘‘persistent or intermittent muscle
contractions, usually involving agonist and antagonist
muscles simultaneously, causing abnormal, often repetitive,
movements, postures, or both’’ (1,2). Cervical dystonia (CD)
is a focal dystonia that is usually primary and characterized
by persistent involuntary contractions of cervical muscles,
causing abnormal head movements or postures (3,4). CD is
one of the most common forms of dystonia and may cause
considerable disability and adversely affect quality of life (5).
Botulinum toxin (BTX) type A is a potent biological neuro-
toxin that produces transient muscle weakness by irrever-
sible presynaptic inhibition of acetylcholine release. Its clinical
use is considered the best treatment for dystonia, and it
produces satisfactory results in most cases, albeit with side
effects, including dysphagia, dry mouth and throat, and voice
changes such as hoarseness, which are frequently described
and may limit the treatment of these patients (6,7).
Dysphagia is described as one of the most frequent side
effects of BTX injection, with an occurrence rate ranging from
10-90% (5,8,9), which can be reduced using ultrasound and
electromyography to guide the BTX injection (8). Despite the
large number of citations and high variability of results,
few studies have assessed swallowing in these individuals
before and after treatment (10-12). Many studies include the
description of symptoms of dysphagia as a single item in
the general questionnaire of side effects after BTX injection
(6,13-15).DOI: 10.6061/clinics/2019/e776
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Changes in swallowing, such as delayed swallowing
reflex and presence of food stasis in the epiglottic vallecula,
have previously been described as changes in the phar-
yngeal phase of swallowing in this population before any
therapeutic intervention (16-18). These changes highlight
the effects of cervical dystonic movements and their muscle
conditions on performing one of the most important func-
tions: eating.
In phase 1 of this study, we aimed to investigate the swal-
lowing perception and complaints of individuals with CD
before and after BTX injection in treatment-naive patients to
analyze the actual relationships among the disease, swallow-
ing and medication before and after treatment.
’ MATERIALS AND METHODS
Study Participants
This is a case-control study of patients with CD. Twenty
patients were randomly selected, according to the flow of
patients in the Movement Disorders Unit, Universidade
Federal de São Paulo – UNIFESP, São Paulo, Brazil. Two
individuals withdrew from the study. Therefore, 18 patients
diagnosed with dystonia, with ages ranging from 15 to
45 years and with a median age of 45 years, were evalu-
ated. This study was approved by the Ethics Committee of
UNIFESP (process number 0700/03) and by the Research
Ethics Committee of the Institute of Education and Research
(Instituto de Ensino e Pesquisa – IEP), Sírio Libanês Hospital,
São Paulo (process 2005/19). The inclusion criteria were as
follows. 1. patients with a confirmed diagnosis of primary or
secondary CD based on clinical examination and on neuro-
imaging, such as computed tomography and/or magnetic
resonance imaging; 2. therapeutic indication of BTX applica-
tion in the craniofacial segment in treatment-naïve patients;
3. agreement to participate in the study after receiving infor-
mation on the project and signing the informed consent form
approved and revised by the Research Ethics Committees of
UNIFESP-EPM and of Sírio Libanês Hospital, where the
swallowing videofluoroscopy examinations were performed.
Patients with concomitant neurological impairments, such as
Parkinson’s disease, Parkinson’s syndrome, cerebral palsy,
stroke before onset of dystonia, or ataxias, individuals
younger than 13 years, and patients who refused to partici-
pate in the study and/or who had previously received BTX
were excluded from the study.
Measures
Neurological evaluation and BTX A injection: All patients
were subjected to a neurological medical evaluation for
diagnosis, classification, and therapeutic indication of BTX.
They were also evaluated and classified before and after
the BTX injection using the scale developed by Tsui et al. (19).
The doses applied were determined during the medical
evaluation. The medication used was abobotulinum toxin
(Dysport - Ipsen Ltd., Slough, Berkshire, UK), diluted in 1.25 ml
saline. The doses ranged from 360 to 720 U, with a mean
of 529.7 total U. Two to three injection points were used per
muscle to maximize the effect of the medication.
Speech therapy and evaluation of swallowing: All indivi-
duals answered a medical history questionnaire before (two
to six days, mean of four days) and after (10 to 15 days, mean
of 12 days) BTX injection because the latter period corres-
ponds to the peak treatment effect. The questionnaire
included specific and direct questions aimed at identifying
swallowing and/or speech complaints. The swallowing-
specific medical history questionnaire consisted of 13
closed-ended questions that were answered with ‘‘yes’’
or ‘‘no’’.
1. Voice complaints: individuals were asked about voice
changes following the onset of cervical dystonia. Individuals
who answered ‘‘yes’’ were asked to describe the changes
they noticed.
2. Voice changes while eating: individuals were asked
about voice changes while eating, as an indication of the
presence of food in the larynx, which is a symptom of
dysphasia.
3. Coughing or gagging while eating: individuals were
asked about the presence and frequency of coughing and/or
gagging during meals.
4. Difficulties swallowing saliva: individuals were asked
about the presence of drooling and difficulties managing or
swallowing saliva.
5. Chewing difficulties: individuals were asked about the
presence of difficulty and/or changes in mastication after the
onset of dystonia.
6. Additional effort required for swallowing solids: indivi-
duals were asked about the need for extra effort to swallow
solids. If they answered ‘‘yes’’, this would indicate difficul-
ties with food bolus propulsion, which is one of the possible
changes in the oral phase of swallowing.
7. Sensation of food stuck in the throat: individuals were
asked about the sensation of food stuck in the throat during
or after eating. If they answered ‘‘yes’’, this would indicate
likely inefficient food bolus propulsion, leading to the
accumulation of food (stasis) in the oro- and/or hypophar-
ynx, which are possible symptoms of changes in the oral
and/or pharyngeal phases of swallowing.
8. Eating fatigue: individuals were asked about worsened
fatigue while eating compared to the conditions before
disease onset. If they answered ‘‘yes’’, this would indicate
likely difficulties with food bolus propulsion and transport
during the oral and pharyngeal phases of swallowing.
9. Increased eating time: individuals were asked about
increases in total eating time. If they answered ‘‘yes’’, this
would indicate increased swallowing difficulties and effort.
10. Reduced appetite: individuals were asked about a
reduced amount of food ingested associated with a lack of
appetite. If they answered ‘‘yes’’, the complaint of lack of
appetite would indicate swallowing difficulties, which are
often masked.
11. Complaint of retching: individuals were asked about
episodes of regurgitation, heartburn, or acid reflux after
eating. If they answered ‘‘yes’’, this would indicate symptoms
of esophageal dysphagia, possibly associated with laryngeal
penetration and/or aspiration events after swallowing.
12. Need to adjust posture while eating: individuals were
asked about the need for postural changes or for performing
a sensory maneuver to momentarily eliminate the dystonic
movement to facilitate eating. If they answered ‘‘yes’’, this
would indicate a possible direct association between the
dystonic movement and dysphagia, and possible improve-
ment after BTX injection would result in elimination of the
movement.
13. Need to adjust eating utensils: individuals were asked
about the need to change their usual eating utensils (for
example, if they began using a spoon instead of a fork). If
they answered ‘‘yes’’, this would indicate signs of altered
oral control of maintaining the food in the mouth and/or
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altered food transport from the plate to the mouth, thereby
contributing to the individuals’ lack of interest in eating.
Data Analysis
The swallowing-specific medical history findings before
and after BTX injection were statistically compared using
McNemar’s test to assess the significance of changes after
administrating the medication.
’ RESULTS
Eighteen individuals with CD were evaluated, inclu-
ding 16 patients with idiopathic and two with secondary
CD. The group consisted of eight men and 10 women, with
a mean age of 45 years. The mean age at disease onset was
39 years, and the mean disease duration was 6.5 years.
Primary dystonia was diagnosed in 83.3% (N=15) of cases,
whereas secondary dystonia was identified in only three
individuals (16.3%). Dystonic rotational movement was
identified in all study subjects. Clinical characteristics
identified using the Tsui scale were used to categorize
individuals as follows: pure rotational torticollis (22.2%,
N=4); mixed rotational torticollis (77.7%, N=14), including
rotational torticollis and retrocollis (38.8%, N=7), rotational
torticollis and anterocollis (16.6%, N=3), and rotational
torticollis and laterocollis (22%, N=4); retrocollis (N=0); and
dystonic tremor (N=6).
All study subjects showed improved dystonia symptoms
post-treatment. The mean dystonia scores according to the
Tsui Scale were 9.05 before and 4.72 after BTX injection.
Abobotulinum toxin (Dysport - Ipsen Ltd., Slough, Berk-
shire, UK) was administered with a mean injection dose of
529.77 U, ranging from 360 U to 720 U.
Table 1 shows that significant differences were found for
swallowing-specific complaints between the period before
and after BTX injection in any questionnaire item, although
slight changes were observed in the overall profile of this
population.
Figure 1 shows that the presence of coughing or gagging
while eating was the most frequent complaint before (9)
and after (11) BTX injection. The curves of both graphs have
similar shapes, showing an increase in the number of com-
plaints of requiring extra effort to swallow solids, sensation
of food stuck in the throat, and eating fatigue.
’ DISCUSSION
Medical history data are usually disregarded in objective
studies. In our study, swallowing-specific medical history
data collected before and after BTX injection showed that CD
patients, when formally and directly questioned, identified
changes and reported complaints that often were character-
istic of their daily lives. Furthermore, regardless of the degree
to which those changes compromised the quality of life of the
patients, they became part of their daily routine and often
resulted in variable adjustments. Such swallowing and/or
voice changes are often not considered to be directly related
to dystonia by patients and/or their relatives.
Figure 1 shows the most frequent complaints before
BTX injection, including voice changes (55.6%), coughing or
choking while eating (50%), increased eating time (50%),
need to adjust posture while eating (55.6%) and difficulties
chewing (44%).
Phono-articulatory changes in dystonia patients are gen-
erally classified as hyperkinetic dysarthrophonia (18,20-22). In
our study, complaints of voice changes were observed in
55.6% of study subjects. We suggest that dystonic movements,
which may involuntarily occur symmetrically or asymmetri-
cally, cause vocal tract instability, directly affecting parameters
such as resonance and voice quality. Furthermore, interrup-
tion of the continuous airflow for sustained vocalization can
also promote constant breaks in sonority, thus affecting the
intelligibility and quality of communication. However, varia-
tions in pitch or loudness, inappropriate pauses, hyper or
hyponasality, articulatory inaccuracy, and reduced speech rate
are characteristic of hyperkinetic dysarthrophonia (18,22-25).
Although dysarthrophonia is apparently unrelated to swal-
lowing changes, they maintain a close relationship because
the same muscles are involved in these two vital functions.
Therefore, if physiological phono-articulatory changes occur,
physiological swallowing changes may also occur.
Swallowing complaints, such as choking, when asked
about in isolation, are often overlooked because patients only
consider choking events when they are sufficiently intense to
compromise breathing. Conversely, when combined with
coughing episodes while eating, choking may indicate the
occurrence of tracheal aspiration, with or without sponta-
neous exit of the material. A rare study on the preinterven-
tion swallowing patterns of patients with CD found that 36%
of patients complained of dysphagia (11). In our study, the
Table 1 - Comparison of patient clinical voice and swallowing complaints before and after botulinum toxin injection (N=18).
Pre-toxin Post-toxin
N % N %
Voice
change in voice quality 10 56% 9 50%
change in voice quality during eating 2 11% 0 0%
Swallowing
coughing and/or choking during eating 9 50% 11 61%
difficulty swallowing saliva 4 22% 3 17%
difficulty chewing 8 44% 5 28%
need for hard swallowing 5 28% 6 33%
residual sensation in the throat 6 33% 8 44%
tired sensation after eating 6 33% 7 39%
requiring a long time to eat 9 50% 8 44%
reduced appetite 7 39% 5 28%
frequent regurgitation 3 17% 1 6%
need for an adapted position during eating 10 56% 6 33%
need for adaptation of cutlery during eating 7 39% 7 39%
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complaint of presence of coughing and/or choking while
eating was reported by nine individuals (50%) before BTX
injection and illustrated the presence of eating difficulties
before drug treatment in this population. When analyzing the
hyperextension posture of individuals or even continuous and
involuntary dystonic movements, we must consider that the
airway remains open or opens and closes abruptly during
swallowing. Therefore, when apnea is necessary, which invol-
ves closure of the airway for its protection and synchrony for
food bolus transport to the stomach, dystonic movements can
interrupt this process and affect postural stability, aggravating
the lack of control over food bolus transport and leading to
possible food bolus penetration and/or pulmonary aspiration
before, during, or after swallowing. However, we believe that
the pathophysiology of CD may directly affect swallowing
and eating.
The need for postural adjustments while eating was one
of the most frequent complaints (55.6%). Many patients
reported a fear of hurting themselves with their utensils
while eating since the presence of dystonic movements may
compromise coordination when transporting food from the
plate to the mouth. The same problem was observed by
Benecke et al. in 2003 (25).
Complaints of chewing difficulties (44.4%) and increased
eating time (50%) directly showed the effect of dystonia on
the muscles involved in the eating process. Thus, the impact
of this disability on the daily life and diet of this population,
including food refusal, lack of pleasure during meals, and
reduced quality of life, can be analyzed, as it compromises
social activities, aggravating reclusion.
Notably, before the drug treatment, a mean of 50% of
patients, when directly asked, reported signs of changes or
difficulties while eating, although this was not a frequent
spontaneous complaint. Few swallowing studies have
been conducted before and after BTX injection, and stu-
dies reporting swallowing-specific medical history data
are even rarer. Comella et al. reported a frequency of 11%,
Munchau et al. reported 58.3%, and Dressler et al. reported
that 9% of the study population complained of dysphagia
before the injection; however, dysphagia complaints were
not specified in any of these studies (10,26-27).
After the BTX injection, the mean number of eating-related
complaints remained at approximately 50%. The individuals
reported the same complaints as those described before the
injection. An additional complaint was the sensation of food
stuck in the throat, which may reflect a mild worsening of the
oral phase of swallowing resulting from changes in food bolus
propulsion or in its passage through the oro- and hypophar-
ynx. These changes often derive from changes in pharyngeal
propulsion, larynx elevation, and/or opening of the phar-
yngoesophageal segment. The posterior wall of the pharynx is
described as the region most susceptible to BTX migration
after its injection into the sternocleidomastoid and scalene
muscles (8) and may also contribute to the sensation of food
stuck in the throat (8,16,17,28), which is associated with valle-
cular stasis. A previous study on various types of dystonia
reported the occurrence of increased sternocleidomastoid mus-
cle contraction time, increased time of initial elevation and
lowering of the larynx, delayed triggering of the swallowing
reflex, and increased cricopharyngeal muscle contraction in CD
patients, which may in turn compromise and/or affect the
dynamics of the pharyngeal phase of swallowing (11).
Coughing and/or gagging complaints increased from
50% pre-BTX to 61.1% post-BTX due to an additional two
individuals with this complaint, who also complained of
increased sensation of food stuck in the throat, which
increased from 33.3% pre-BTX to 44.4% post-BTX. We believe
that in both cases, the effect of BTX on the pharynx may
explain such complaints, in addition to the heightened
attention of these individuals during eating because they
were participating in a study on their specific swallowing
complaints (Table 1).
However, we observed and concluded that CD alone can
affect the swallowing and speaking functions because it is a
Figure 1 - Comparison of swallowing complaints before and after botulinum toxin injection.
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neurological alteration and compromises both muscle tone
and functional aspects of the cervical muscles. The speed,
accuracy, and performance of the vital function of eating are
compromised. Despite the large functional gain and impro-
ved quality of life of these individuals, treatment with BTX
may exacerbate pre-existing changes in the phono-articulatory
system responsible for speaking and swallowing.
Based on the possible pretreatment alterations, we suggest
that CD patients could be subjected to a swallowing evalu-
ation before the drug intervention, thereby enabling the
medical team to advise them on postural adjustments and
safer food consistencies during peak BTX activity. Thus,
alertness, knowledge, and food safety measures can prevent
complications resulting from possible tracheal aspirations
and can promote safe and functional food intake while main-
taining hydration and nutritional support.
We suggest that future studies compare the specific
swallowing complaints in individuals with CD pre- and
post-treatment with BTX and perform an objective swallow-
ing study of these individuals.
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